Healthcare & Life Sciences

Mammoth Biosciences CRISPR Dystrophin Editing Patent Application

USPTO published patent application US20260097134A1 assigned to Mammoth Biosciences, Inc. covering CRISPR-Cas systems and methods for editing human dystrophin genes to treat Duchenne muscular dystrophy (DMD). The application includes compact Type V CRISPR-associated proteins, RNA-dependent DNA polymerase, and guide nucleic acids for gene modification therapies.

Recombinant AAV Vectors for Treating Muscular Dystrophy

USPTO published patent application US20260097132A1 assigned to Sarepta Therapeutics, Inc. covering recombinant adeno-associated virus (rAAV) vectors for expressing human micro-dystrophin gene to treat muscular dystrophy, including Duchenne Muscular Dystrophy. The application includes methods for genotyping DMD gene to determine rAAV gene therapy contraindications. Filing date was September 22, 2023.

Fungal Spore Production Method Using Dual Liquid Medium

The USPTO published patent application US20260098242A1 covering a method for producing fungal spores using a dual liquid medium system. The first medium has a lower carbon content than the second medium. Inventors: Van De Zilver Eric, Laurens Van Leeuwen. Application filed September 26, 2023; published April 9, 2026.

Macrocyclic CFTR Modulators for Cystic Fibrosis

USPTO published patent application US20260098060A1 for macrocyclic CFTR modulators for treating cystic fibrosis. The application covers compounds of Formula (I), their preparation, pharmaceutical salts, and uses as CFTR modulators or in combination with CFTR potentiators/correctors. Inventors include Martin Bolli, Christine Brotschi, John Gatfield, and others. The application was filed on September 14, 2023.

HPV Vaccine Peptide Constructs with Ligand-Inducible Gene Switch Systems

The USPTO published patent application US20260098063A1 titled 'Human Papillomavirus Vaccines and Uses of the Same.' The application covers engineered HPV molecular vaccine constructs incorporating ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as cytokines, in host cells. The application was filed on July 7, 2025, by inventors including Douglas E. Brough and Cheryl G. Bolinger. Patent applications are published for informational purposes and do not grant enforceable rights until issued as a patent after examination.

LANMODULIN ORTHOLOGS WITH IMPROVED RARE EARTH SEPARATION PERFORMANCE

USPTO published patent application US20260098064A1 for lanmodulin orthologs (proteins) designed to bind rare earth metals with enhanced REE/REE selectivity. The application covers proteins with four EF hand motifs, methods of using the proteins, and devices/kits containing them. The invention has applications in rare earth element separation and processing.

Peptide Compositions Targeting β-Catenin for Treatment of Endometriosis

USPTO published patent application US20260098059A1 for peptide compositions targeting β-catenin for treatment of endometriosis. The application covers peptides that bind β-catenin and prevent nuclear translocation, modulating the canonical Wnt pathway. Filed October 10, 2025 under Application No. 19355926. Patent rights are not yet granted; applicants seeking to develop similar therapies should review the published claims for freedom-to-operate considerations.

Advagene Biopharma Patent for Asthma Treatment Using Detoxified E. coli Labile Toxin

USPTO published patent application US20260098065A1 assigned to Advagene Biopharma Co., Ltd. covering methods for treating eosinophil-driven inflammation including severe asthma using a composition for mucosal administration comprising detoxified Escherichia coli labile toxin.

Ovarian Cancer Diagnostic Marker, Urteste S.A

Ovarian Cancer Diagnostic Marker, Urteste S.A

EphA2-binding Peptide and Composition Patent Application

The USPTO published patent application US20260098061A1 for an EphA2-binding peptide and composition comprising such peptides. The application, filed on September 28, 2023, lists 13 inventors including Takanori Aoki and others. The patent covers peptides that bind to the Eph receptor A2 (EphA2) and compositions containing such peptides, with CPC classifications C07K 7/64 and A61K 47/64.

Lipid Particles Comprising Variant Paramyxovirus Attachment Glycoproteins

USPTO published patent application US20260098062A1 assigned to Sana Biotechnology, Inc. covering lipid particles comprising variant Paramyxovirus attachment glycoproteins with reduced glycosylation and methods for their production and use. The application (originally filed September 21, 2023) covers viral-based particles with modified G/H proteins and their therapeutic applications.

Endotracheal Lung Suction System for Selective Lung Drainage

The USPTO published patent application US20260097175A1 assigned to Roberts Innovations, LLC covering an endotracheal lung suction system for selective lung drainage. The system includes an endotracheal tube with an implantation balloon, a suction assembly with proximal valve, and an inner suction catheter with an inflatable securing device. The invention enables selective drainage of user-selected lungs through a dual-lumen catheter design.

Tube Support Apparatus and Methods for Stabilizing Medical Tubing

The USPTO published patent application US20260097176A1 for a tube support apparatus designed to stabilize medical tubing relative to patients. The apparatus includes a brace for patient attachment, a support with a groove and transverse channel for receiving tubing, and a clamp with a padded bar to secure the tube. The application was filed on October 3, 2025, under application number 19349402.

SleepSanity LLC Sleep Mask Patent Application

USPTO published patent application US20260097179A1 for SleepSanity LLC's sleep mask with LED lighting, adjustable opacity lens, and fiber optic light transmission system. The application, filed October 7, 2024, covers a wearable sleep device with silicone components and power source connectivity. CPC classifications include A61M 21/02 and A61N 5/0613, indicating medical and therapeutic lighting applications.

Medical Securement Device Secures Tubes to Patients

The USPTO published patent application US20260097177A1 for a medical securement device designed to secure medical tubing to patients. The device features a flat base with a central circular opening and a cylindrical wall with adhesive on its inner surface to fix medical tubes at selected positions. The application was filed on October 13, 2025.

PEP Buddy Oral Device US20260097174A1, Apr 09

PEP Buddy Oral Device US20260097174A1, Apr 09

Airway Management System Patent Application US20260097178A1

USPTO published patent application US20260097178A1 for an airway management system invented by Ming Yang. The system includes a breathing circuit connector component, inner tube component, connecting tube, and either a laryngeal mask component with telescopic tube or an endotracheal tube component. The application covers multiple embodiments with various connector configurations for medical ventilation applications.

Medical Eyeshade EEG Detection System

The USPTO published patent application US20260097180A1 for a medical eyeshade with integrated electroencephalogram detection. Inventor Siyang Liang's system includes an eyeshade body with EEG acquisition unit and controller that converts brain electrical signals into communication signals for external transmission. The flexible circuit board passes through an opening to contact the wearer's forehead.

Tibial Insert Knee Implant with Sensors

USPTO published patent application US20260096895A1 for a tibial insert knee implant with integrated sensors, filed by Damon J. Servidio and Chad Bean. The invention comprises a tibial baseplate, tibial insert with articular surface, at least one sensor and battery housed in a void, and a detachable sealing case, with a minimum thickness of 2mm. Medical device manufacturers in the orthopaedic implant sector should monitor for potential licensing or competitive implications.

Methods to Reconstruct Bone and Joint Surfaces in Elbow, Wrist, or Hand Joint

The USPTO published patent application US20260096893A1 filed by Subchondral Solutions, Inc. The application discloses methods for reconstructing bone and joint surfaces in elbow, wrist, or hand joints using subchondral bone techniques for therapeutic treatment of joint defects without requiring full or partial joint replacement. The filing date was September 21, 2023.

Convertible Glenoid Implant Shoulder Reconstruction

The USPTO published patent application US20260096898A1 for a convertible glenoid implant system developed by Howmedica Osteonics Corp. The invention describes a modular shoulder reconstruction device comprising a base plate with support structures and a removably coupled articular component featuring engagement structures and recessed portions for abutting subchondral bone. The application was filed on December 12, 2025, and published April 9, 2026.

Sacroiliac Joint Implant System Published Apr 09

Sacroiliac Joint Implant System Published Apr 09

Modular Glenoid Implant Shoulder Replacement System

The USPTO published patent application US20260096896A1 on April 9, 2026, disclosing a modular shoulder replacement system invented by Bradley Carofino. The system uses multiple small implant plates placed strategically in the shoulder joint to reduce the rocking horse phenomenon, preserve bone stock, and allow minimally invasive procedures with customizable fit for patient-specific wear patterns. The application was filed on October 4, 2024, under application number 18907275.

MPN Treatment Methods with Therapeutic Compounds

USPTO published patent application US20260097028A1 for therapeutic methods treating myeloproliferative neoplasms (MPN) including polycythemia vera, essential thrombocythemia, and myelofibrosis. The application covers combination therapies using compounds of Formula (I) or Formula (II) with JAK inhibitors, IDH inhibitors, PD-1/PD-L1/PD-L2 inhibitors, interferons, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, or nucleoside analogs. Filed February 18, 2025, application number 19055807.

Cancer Treatment Patent Using Quinoline Derivative and Antibody

The USPTO published patent application US20260097030A1 on April 9, 2026, disclosing a therapeutic combination of a quinoline derivative and an antibody for treating cancer, specifically lung and liver tumors. The application names 14 inventors and was filed on April 11, 2025. This publication makes the application publicly available but does not grant any enforceable patent rights.

mRNA, Protein Vaccine Compositions for Influenza

The USPTO published patent application US20260097112A1 by inventors Jacob Glanville et al. covering vaccine compositions comprising combinations of influenza antigens. The application discloses mRNA/LNP, recombinant protein, virus-like particle (VLP), and DNA vaccine formulations. Filing date was October 17, 2025.

Ypsomed AG Injection Device with Improved Conveying Element Patent Application

The European Patent Office published patent application EP4159257A1 for an injection device with improved conveying element, filed by Ypsomed AG. The application lists six inventors and covers IPC classifications A61M 5/20, A61M 5/24, and A61M 5/315 relating to injection mechanisms. The application is designated for validation in 28 European member states including Germany, France, the United Kingdom, Italy, and Spain.

Atovaquone Patent, Mast Cell Inflammatory Disease Treatment

Atovaquone Patent, Mast Cell Inflammatory Disease Treatment

Modified-Release Minoxidil Compositions and Methods for Hair Loss Treatment

The USPTO published patent application US20260097035A1 filed by inventor Reid Waldman on December 10, 2025, covering modified-release minoxidil compositions for treating hair loss. The application discloses pharmaceutical formulations for oral administration of modified-release minoxidil and methods of using the compositions for hair loss treatment.

Neuroplasticity Treatment Method with Neurostimulation and Dopamine Agonist for Depression

USPTO published patent application US20260097224A1 disclosing a method for treating neuroplasticity-related conditions by administering a dopamine receptor agonist combined with neuroplasticity-modulating drugs prior to or simultaneously with targeted energy-based neurostimulation, repeated within one day. The preferred embodiment targets depression using transcranial magnetic stimulation. Inventors are Donald A. Vaughn and Jonathan A.S. Downar, with application number 19274159 filed July 18, 2025.

Proton Pump Inhibitors for Inhibition of Aortic Valve Calcification

USPTO published patent application US20260097026A1 for the use of proton pump inhibitors including prazole compounds to inhibit calcification of aortic valves, treating aortic sclerosis and stenosis. The application was filed on October 3, 2023, with inventors Arsenii Zabirnyk, Ingvar Jarle Vaage, and Kåre-Olav Stensløkken. The invention is classified under CPC codes A61K 31/4439 and A61P 9/10.

Plant-Based DHA and Berberine Compositions for Treating Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease

The USPTO published patent application US20260097024A1, filed October 7, 2025, covering compositions and methods for treating obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease using synergistically effective amounts of plant-based DHA and berberine. Inventors are Roger Catarino and William Kuhne. The application has been made publicly available as part of the 18-month patent publication process.

Cysteamine for Treatment, Mitigation and Prevention of SARS-CoV-2 Infections

USPTO published patent application US20260097007A1 for cysteamine and derivatives for treating COVID-19 and related viral infections. Inventors are Jess Thoene and Robert Gavin. The application (No. 19415604) was filed December 10, 2025, and published April 9, 2026.

Injectable Composition For Drug Delivery Using Poly Ortho Ester Polymer

USPTO published patent application US20260096985A1 for an injectable drug delivery composition using poly ortho ester (POE) polymer. The composition includes one or more solvents and therapeutic agents, including a basic therapeutic agent, with the POE polymer having a glass transition temperature between approximately −10°C and 110°C per ASTM E1640-18. Inventors are Vijay Gyanani and Jeffrey Haley, with European Application No. 19348865 filed October 3, 2025.

RSV Polyanhydride Nanoparticle Vaccine

The USPTO published patent application US20260096999A9 for a respiratory syncytial virus (RSV) vaccine using polyanhydride nanoparticle delivery technology. The application, filed February 17, 2022 by inventors Steven M. Varga and Kevin L. Legge, claims vaccine compositions including RSV F protein in pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles, with optional adjuvant. Patent applications are published to inform the public and allow monitoring of emerging IP positions in the pharmaceutical sector.

ALOX15 Inhibitor Patent Application for Respiratory Disorder Treatment

The USPTO published patent application US20260097102A1 on April 9, 2026, disclosing ALOX15 inhibitors for treating respiratory disorders. Inventors Julie Horowitz and Aris Baras filed the application on October 21, 2025 (Application No. 19364245). The patent covers methods of treating respiratory disorders, identifying at-risk subjects, and detecting ALOX15 variant nucleic acids and polypeptides.

UV/HEV Light Filtering Compounds and Their Use

USPTO published patent application US20260098007A1 for compounds and their use in filtering ultraviolet (UV) and high-energy visible (HEV) light, invented by Micah Nelp and Anthony Young. The compounds may be used in compositions, consumer products, and packaging materials. This patent grant establishes intellectual property rights for the inventors.

Shionogi Fused Ring GLP-1 Receptor Agonist Patent Application

The USPTO published patent application US20260097037A1 by Shionogi & Co., Ltd. on April 9, 2026, covering fused ring compounds as GLP-1 receptor agonists for pharmaceutical use. The application was filed on September 21, 2023, under application number 19112403. The compounds are represented by formulas (I) and (II), with various substituents including phenyl groups and heterocyclic rings.

Conjugates for Cancer Treatment - Patent Application US20260097117A1

USPTO published patent application US20260097117A1 for conjugates comprising a binding moiety and an immunomodulatory imide compound, such as substituted isoindoline compounds, useful for treating cancer. The application was filed October 2, 2025, by inventors Nathan Fishkin and Peter U. Park, with a publication date of April 9, 2026.

Metalloenzyme Inhibitor Compounds (Patent Application US20260097034A1)

USPTO published patent application US20260097034A1 for metalloenzyme inhibitor compounds. The application was filed on October 2, 2025 (Application No. 19348647) by inventors Steven Sparks, Christopher M. Yates, Sammy R. Shaver, and William J. Hoekstra. The patent covers compounds having metalloenzyme modulating activity and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes.

Fluoro Beta-Carboline Compounds, Bone Formation Method

USPTO published patent application US20260097041A1 for fluoro beta-carboline compounds and methods of promoting bone formation. The application (No. 19202018, filed May 8, 2025) covers compounds of Formula I and their use in orthopedic devices, periodontal devices, and treatment of renal disease, diabetes, bone loss, and cancer. Inventors include Debra Ellies, F. Scott Kimball, and Robert N. Young.

COMPOUNDS AND USES THEREOF - Senolytic Compounds for Aging Treatment

The USPTO published patent application US20260097022A1 for senolytic compounds and methods for treating aging-related conditions. The application covers screening of 2,352 compounds for senolytic activity and trained neural networks to predict activity across over 800,000 molecules. Compounds disclosed bind to Bcl-2 proteins and reduce senescent cell burden. Application filed October 2, 2025; published April 9, 2026.

Tetrahydroquinoline Compounds As Antitumor Agents

USPTO published patent application US20260097029A1 for tetrahydroquinoline compounds of Formula (I) and their salts as disruptors of the FANCM/BTR interaction, useful for hampering FANCM localization to telomeres in tumor treatment. The application (No. 19112485) was filed September 22, 2023 by inventors Sandro Cosconati, Stefano Tomassi, Salvatore Di Maro, and Hilda Amelia Pickett. CPC classifications include A61K 31/4709, A61P 35/00, and C07D 215/06.

Plasmodium Falciparum Blood Stage Inhibitor Compounds for Malaria Treatment

USPTO published patent application US20260097046A1 disclosing compounds that inhibit Plasmodium falciparum asexual blood stage parasites for malaria treatment. The compounds exhibit sub-millimolar potency against intraerythrocytic stages and are soluble for oral administration. Inventors include Alicia N. Wagner, Roger Trombley, and 8 others. Application filed December 12, 2025.

Bioanalytical Method Validation for Biomarker Concentrations Guidance

FDA's Center for Drug Evaluation and Research issued guidance FDA-2017-D-6821 to help sponsors validate bioanalytical methods used to evaluate biomarker concentrations in drug and biologic development programs. The guidance applies to sponsors of investigational new drug applications (INDs), new drug applications (NDAs), biologics license applications (BLAs), and abbreviated new drug applications (ANDAs). It addresses method validation for biomarker analysis in both clinical study samples and nonclinical study samples.

Determination That BILTRICIDE (Praziquantel) 600mg Tablet Was Not Withdrawn From Sale

The FDA has issued a determination that BILTRICIDE (Praziquantel) oral tablet, 600 milligrams, was not withdrawn from sale for reasons of safety or effectiveness. This determination affects pharmaceutical manufacturers, healthcare providers, and patients who rely on this anti-parasitic medication. The notice confirms the drug remains available on the market and was not subject to removal due to regulatory safety concerns.

HRSA AIDS Drug Assistance Program Data Report Extension Request

The Health Resources and Services Administration (HRSA) is seeking public comment on extending OMB Control No. 0915-0345 for the AIDS Drug Assistance Program (ADAP) Data Report. The comment period closes on May 13, 2026. This is an administrative information collection extension request for an existing data reporting mechanism used to monitor ADAP program activities.

SAMHSA Information Collection OMB Review Request

SAMHSA, a division of HHS, has submitted an information collection request to OMB for review under the Paperwork Reduction Act. The notice announces a 30-day public comment period on proposed data collection activities related to substance abuse and mental health services programs. This is a standard administrative action to gather feedback on existing or modified information collection requirements.

HRSA Extends Funding to University of Utah for Emergency Medical Services for Children Data Center

The Health Resources and Services Administration (HRSA) has issued a Notice extending funding to the University of Utah for the Emergency Medical Services for Children Data Center (EDC). The document, published in the Federal Register on April 13, 2026, is designated as Notice document number 2026-07035, appearing at citation 91 FR 18867.

Medicare Mental Health Coverage Provider Guidelines Booklet

CMS Medicare Learning Network published a booklet (MLN1986542) providing guidelines on Medicare coverage for mental health services. The publication explains which providers are eligible to furnish treatment and outlines Medicare coverage policies for mental health care.